Histide AG

Histide™ is pioneering Recoding Therapeutics™, a novel therapy using non-mutagenic extracellular technologies to direct cell fate.

Based on the universal understanding of the mechanisms underlying mammalian cell behavior, Histide™ has created an innovative platform of complex microenvironments with the capacity to dictate the precise commitment of various cell types. These include cells from different tissue origins and at contrasted differentiation stages, ranging from stem cells to specialized mature cells.

In contrast to previously developed gene therapies or RNA based therapies, the Histide™ technology has the major advantage of not requiring the introduction of foreign molecules inside the cell which in turn may be irreversibly harmful to its functioning. Recoding Therapeutics™ are instead an extracellular technological approach that promotes and stimulates the cell's natural capacities to redirect its own fate by integrating accurate micro-environmental recoding signals. This allows for a precise and fine functional tuning that offers a master control over the cell biology. Recoding Therapeutics™ are the closest to the natural cell physiology, hence, providing significantly improved safety and efficacy. They have the potential to address a wide range of altered cell conditions and diseases through the regeneration of a large majority of the human body tissues.

Histide™ has created a broad and disruptive intellectual property portfolio including Recoding Molecules™, Micro-environmental Design and Therapeutical Development being a technological break-through with vast indication spectra of pharmaceuticals, medical devices and medical cosmetics.

Based in Europe, Histide™ has developed strong international collaborations with leading Universities and Institutes around the globe in order to make its expertise and technology known and promote the Recoding Therapeutics™.